Stock PSTX POSEIDA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Poseida Therapeutics, Inc.

Equities

PSTX

US73730P1084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-18 pm EDT 		5-day change 1st Jan Change
2.64 USD -6.05% Intraday chart for Poseida Therapeutics, Inc. -4.00% -21.43%
May. 14 Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises MT
May. 14 Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Poseida Therapeutics Q1 Net Loss Narrows, Revenue Rises
MT
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q1 Revenue $28.1M
MT
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos
MT
Malin Corp investee signs agreement with Astellas Pharma
AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences
DJ
Poseida Therapeutics, Inc. and Xyphos Biosciences, Inc. Enter into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
CI
Poseida Therapeutics, Inc. Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-Allo1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q4 Revenue $25M
MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Poseida Therapeutics, Inc. Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology Annual Meeting
CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Posts Q3 Revenue $9.4M
MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (PSTX) POSEIDA THERAPEUTICS Reports Q2 Revenue $20M
MT
Poseida Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Poseida Therapeutics Secures $50 Million Strategic Investment From Astellas; Shares Gain
MT
Poseida Therapeutics Says US FDA Clears Investigational New Drug Application for B-cell Malignancies Treatment Candidate
MT
Poseida Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Poseida Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PSTX Stock
  4. News Poseida Therapeutics, Inc.
  5. Highlights